JPRN-UMIN000000812已完成未知
A Study To verify the efficacy of ROsuvastatin 2.5 mg as an aggressive lipid lowering therapy for hypercholesterolemia-1 - ASTRO-1
Graduate Scholl of Medicine, the University of Tokyo0 个研究点目标入组 100 人开始时间: 2007年8月31日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with Severe hypertension (SBP>=180 mmHg or DBP>=110 mmHg) 2) Patients with type I diabetes 3) Patients with familial hypercholesterolemia 4) Patients with fasting serum TG>=400 mg/dL 5) Patients who have experienced cerebrovascular diseases within 3 months 6) Patients with serious heart failure (NYHA class III to IV) 7) Patients undergoing PTCA/CABG during the study period 8) Patients with active hepatic disease (ALT or AST>100 IU/L or total bilirubin> 2.5 mg/dL) 9) Patients with renal disorder (Cr>=2.0 mg/dL or Ccr<30 mL/min/1.73 m2) 10) Patients with CK>1000 IU/L 11) Pregnant women, impregnable women, or those who hope to be pregnant during the study period 12) Patients with hypothyroidism, hereditary muscular diseases (muscular dystrophy, etc.) or familial history of these diseases. Patients with history of drug-related muscular disorder 13) Patients with drug abuse or alcoholism 14) Patients who use prohibited concomitant drugs* or who might use such drugs during the study period 15) Patients who are ineligible in the opinion of the investigator *Statines, fibrates, anion exchange resin, cholesterol absorption inhibitors, probucol, nicotine acids, phytosterol, other anti hypercholesterolaemia drugs, immune suppressing drugs
研究者
相似试验
进行中（未招募）
不适用
A phase II study to investigate the efficacy of RAD001 (Afinitor®, everolimus) in patients with irresectable recurrent or metastatic differentiated, undifferentiated (anaplastic) and medullary thyroid carcinoma - THYRRAD, CRAD001CNL08TPatients with irresectable recurrent or metastatic differentiated, undifferentiated (anaplastic) and medullary thyroid carcinoma will be treated in a phase II study to investigate the efficacy of RAD001 (Afinitor®, everolimus).EUCTR2009-016669-27-NLeiden University Medical Center
已完成
2 期
A phase II study to investigate the efficacy of RAD001 (Afinitor ®, everolimus) in patients with irresectable recurrent or metastatic differentiated, undifferentiated (anaplastic) and medullary thyroid carcinomathyroid cancerNL-OMON35047eids Universitair Medisch Centrum42
已完成
2 期
Phase II Clinical Study Evaluating the Efficacy and Safety of Cetuximab Rechallenge in Patients with Wild-Type RAS, Unresectable, Progressive/Recurrent Colorectal Cancer Refractory to Fluoropyrimidines, Oxaliplatin, Irinotecan, Cetuximab and Bevacizumab: The E-Rechallenge TrialColorectal cancerJPRN-UMIN000016439Public Health Research Foundation50
招募中
2 期
A randomized phase II study to evaluate efficacy of negative pressure wound therapy on prophylaxis of the incisional hernia after reversal of temporaly diverting stomatemporally diverting stoma to be planned to have closedJPRN-UMIN000030936Aichi Medical University70
进行中（未招募）
1 期
Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants with High-Risk Non-Muscle Invasive Bladder Cancer Unresponsive to Intravesical Bacillus Calmette-Guerin who are Ineligible for or Elected Not to Undergo Radical CystectomyEUCTR2020-002646-16-PTJanssen-Cilag International NV200